This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pacific Biosciences Appoints Michael J. Glynn As Chief Commercial Officer

Pacific Biosciences of California, Inc. (NASDAQ: PACB), provider of Single Molecule Real Time (SMRT ®) sequencing products, today announced the appointment of Michael J. Glynn as Chief Commercial Officer.

Michael Glynn has more than 40 years of experience in global commercial operations. Prior to joining Pacific Biosciences, Mr. Glynn served as Regional President, Japan - Asia Pacific and Senior Vice President at Genzyme Corporation. In this role, he was responsible for leading and managing Genzyme's businesses in Japan and Asia Pacific from the company’s regional headquarters in Singapore.

Prior to joining Genzyme in January 2007, Mr. Glynn was with Boston Scientific for seven years, most recently as President of its Endovations division in the United States, and prior to that as Vice President and General Manager, Asia, Middle East, and Turkey. From 1995-2000 he was President and CEO of Codman Group, a developer of healthcare decision support software and home telemedicine systems (formerly Caremonitor, Inc.). He also spent seven years with Memtec Limited as President of Memtec Japan and President of Memtec America. Before joining Memtec he spent ten years with Baxter International in Australia and the United States where he held a variety of management positions in manufacturing, quality assurance, marketing, and strategic planning. Earlier in his career Mr. Glynn held a variety of manufacturing and technical management positions with companies in Australia and England, including Burroughs Wellcome, Estee Lauder, and Elizabeth Arden. He holds an M.B.A. from Macquarie University in Sydney and a B.S. from the National University of Ireland.

“Michael has exceptional commercial experience with an emphasis on customer satisfaction and support for industry-leading companies operating in global markets,” said Hugh Martin, Chairman and Chief Executive Officer of Pacific Biosciences. “He has excellent capabilities to lead the next phase of our commercialization strategy for the PacBio RS, and his deep experience with clinical products will be extremely important as next generation sequencing moves closer to patient care.”

In this new position, Mr. Glynn will oversee the day-to-day management of Pacific Biosciences’ commercial operations, including all field sales, support and marketing activities .

“As someone who has lived and worked on four continents I am thrilled to be joining the exceptional team at Pacific Biosciences as the company ramps up its commitment to providing commercial operations around the world,” said Mr. Glynn. “PacBio’s recently introduced, game-changing technology has already shown the tremendous impact it can have in public health applications such as pathogen detection. I look forward to helping the company build a world-class commercial operation that will create further value for our customers.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs